Type of Assessment:
Malignant mesothelioma with a novel BAP1 germline frameshift mutation treated with dual immune checkpoint inhibitors: A case report
Oncology Letters 2025 May 21 [Link] Na Zhou, Mingying Wu, Chenyu Wang, Mingming Yuan, Yuejuan Cheng Huanwen Wu, Xin Gao, Shuangni Yu, Lin Zhao Abstract Germline pathogenic mutation of the BAP1 gene is a common molecular event in malignant mesothelioma (MM). A patient with a positive family history of tenacious peritoneal effusions presented with hydropneumothorax…
Read MoreCo-targeting of VEGFR2 and PD-L1 promotes survival and vasculature normalization in pleural mesothelioma
Oncoimmunology 2025 December [Link] Sophie Rovers, Jonas Van Audenaerde, Ruben Verloy, Jorrit De Waele, Louize Brants, Christophe Hermans, Ho Wa Lau, Céline Merlin, Maria Möller Ribas, Peter Ponsaerts, Steven Van Laere, Filip Lardon, An Wouters, Scott A Fisher, Jan van Meerbeeck, Elly Marcq, Evelien Smits Abstract Pleural mesothelioma (PM) is an aggressive cancer caused by…
Read MoreCisplatin potentiates PD-L1 expression more robustly than pemetrexed in malignant pleural mesothelioma: Temporal dynamics revealed by cellular and xenograft analyses
Pathology, Research, and Practice 2025 July [Link] Zhenghua Zhang, Wenjun Gao, Feng Yuan, Yubin Hu, Xiaoyu Tuo, Liangping Luo, Xiaonan Tang, Shasha Shen, Yang Tian, Dan Han Abstract Objective: Chemotherapy may modulate PD-L1 expression in malignant pleural mesothelioma (MPM), influencing immune checkpoint inhibitor (ICI) efficacy. We compared cisplatin (CDDP) and pemetrexed (PEM) on PD-L1 dynamics…
Read MoreNational Guidelines for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Malignancies: A Worldwide Systematic Review and Recommendations of Strength Analysis
Annals of Surgical Oncology 2025 August [Link] Marco Tonello, Carola Cenzi, Elisa Pizzolato, Manuela Martini, Pierluigi Pilati, Antonio Sommariva Abstract Background: National guidelines (GLs) for surgical cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of peritoneal malignancies (PMs) vary across countries, scientific societies, and government agencies. This study aimed to systematically review and…
Read MoreSarcomatoid mesothelioma vs. myogenic sarcoma: a strong case for diagnostic electron microscopy: a case report
Ultrastructural Pathology 2025 May 25 [Link] Nadine H Oury, Katherine Killian D O, Tim D Oury Abstract Mesothelioma is often considered a difficult diagnosis due to its rarity, the wide variety of histological patterns and the propensity of metastasis from cancers of unknown origin to serosal surfaces. The advent of numerous new immunochemical markers has…
Read MoreDual Immunotherapy for Pericardial Mesothelioma That Developed After a Decade-Long Idiopathic Pericarditis: A Case Report
Respirology Case Reports 2024 May 26 [Link] Beatriz Grau Mirete, Paula Rodriguez Paya, Mariano Martinez Marin, Asia Ferrández Arias, Miguel Borregón Rivilla, Antonio David Lazaro Sanchez, Pedro Morillas Blasco, Alvaro Rodriguez-Lescure, Javier David Benítez Fuentes Abstract Malignant pericardial mesothelioma (MPeM) is exceptionally rare, and its association with long-standing idiopathic pericarditis remains unreported. We present a…
Read MoreA four-miRNA signature as a potential biomarker of malignant mesothelioma patients from hand-spinning asbestos exposed area in Eastern China
Ecotoxicology and Environmental Safety 2025 July 1 [Link] Lijin Zhu, Shibo Ying, Xin Su, Wenke Yu, Kaili Yan, Wei Shen, Shuaiyue Hu, Zhaoqiang Jiang, Hailing Xia, Lingfang Feng, Yan Zeng, Junqiang Chen, Xing Zhang, Jianlin Lou Abstract Malignant mesothelioma (MM) is an aggressive malignant tumor of mesothelial origin that develops mainly in the parietal pleura…
Read MoreKEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma
Cancer Science 2025 May 23 [Link] Takashi Kijima, Terufumi Kato, Yasushi Goto, Kozo Kuribayashi, Koji Mikami, Yoshiki Negi, Shuji Murakami, Tatsuya Yoshida, Masae Homma, Akira Wakana, Kazuo Noguchi, Nobukazu Fujimoto Abstract Pleural mesothelioma (PM) is an inflammatory cancer linked with asbestos exposure and has a poor prognosis. We report results of the phase 1b KEYNOTE-A17…
Read MoreFrom asbestos exposure to carcinogenesis: Transcriptomic signatures in malignant pleural mesothelioma
Experimental and Molecular Pathology 2025 May 20 [Link] Diletta Rosati, Bianca Giulia Maurizi, Viola Bianca Serio, Debora Maffeo, Angela Rina, Francesca Mari, Maria Palmieri, Antonio Giordano, Elisa Frullanti Abstract Background: The incidence of malignant pleural mesothelioma (MPM) has surged due to widespread asbestos exposure, particularly since the mid-20th century. Despite significant advancements in cancer treatment,…
Read MoreA bibliometric analysis of malignant pleural mesothelioma from 2010 to 2023
Journal of Thoracic Cancer 2025 April 30 [Link] Sheng Chen, Ce Zhao, Ruiqi Liu, Wenjie Jiao Abstract Background: Malignant pleural mesothelioma (MPM) is an aggressive tumor originating from the mesothelial lining of the pleural cavity. It is characterized by extensive nodular pleural thickening and has a propensity to invade the pleural adipose tissue and adjacent…
Read More